Skip to main content
Erschienen in: Lung 3/2013

01.06.2013

Microbiological Diagnosis and Antibiotic Therapy in Patients with Community-Acquired Pneumonia and Acute COPD Exacerbation in Daily Clinical Practice: Comparison to Current Guidelines

verfasst von: Angelika Reissig, Christine Mempel, Ulrike Schumacher, Roberto Copetti, Florian Gross, Stefano Aliberti

Erschienen in: Lung | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this secondary analysis was to evaluate current microbiological approaches, microbiology, and antibiotic therapy in patients with community-acquired pneumonia (CAP) and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in clinical practice and to compare them with current international guidelines.

Methods

A total of 362 patients with suspected CAP were enrolled in 14 European centers in a prospective multicenter study.

Results

A total of 279 inpatients (CAP, n = 222; AECOPD, n = 57) were evaluated. A total of 83 (37 %) CAP patients and 25 (44 %) AECOPD patients did not undergo any microbiological tests. In patients with CAP/AECOPD, blood culture was performed in 109 (49 %)/16 (28.1 %), urinary antigen tests for Legionella pneumophila in 67 (30 %)/9 (16 %), and sputum investigation in 55 (25 %)/17 (30 %), respectively. The most frequent pathogens in CAP were Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae, L. pneumophila, Staphylococcus aureus, and Enterobacter cloacae; in AECOPD they were Escherichia coli, Haemophilus haemolyticus, Haemophilus influenzae, and Moraxella catarrhalis. All CAP patients (mean = 11.1 days) and 35 (61.4 %) of AECOPD patients (mean = 8.9 days) received antibiotics. CAP patients were given mostly aminopenicillin with β-lactamase inhibitors and AECOPD patients were given mostly cephalosporins.

Conclusions

Pathogens isolated in CAP and AECOPD and the antibiotic therapy used are in good accordance with the guidelines. Blood culture, recommended for all CAP patients, was performed in only 50 % of the cases and antibiotic therapy lasted longer than the suggested 5–7 days. Therefore, international guidelines regarding performance of blood culture and duration of antibiotic therapy should be adopted more often. This duration was independent of the number of isolated pathogens and number of symptoms on admission. Therefore, the question arises as to whether microbiological data are necessary only for patients who are resistant to initial therapy.
Literatur
1.
Zurück zum Zitat Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M et al (2011) Joint task force of the European respiratory society and European society for clinical microbiology and infectious diseases. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect 17(Suppl 6):1–59PubMedCrossRef Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M et al (2011) Joint task force of the European respiratory society and European society for clinical microbiology and infectious diseases. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect 17(Suppl 6):1–59PubMedCrossRef
2.
Zurück zum Zitat Höffken G, Lorenz J, Kern W, Welte T, Bauer T, Dalhoff K et al (2009) Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the competence network CAPNETZ Germany. Pneumologie 63:e1–e68PubMedCrossRef Höffken G, Lorenz J, Kern W, Welte T, Bauer T, Dalhoff K et al (2009) Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the competence network CAPNETZ Germany. Pneumologie 63:e1–e68PubMedCrossRef
3.
Zurück zum Zitat Global strategy for the diagnosis, management, and prevention of chronic obstuctive pulmonary disease. www.goldcopd.org. Accessed Feb 2013 Global strategy for the diagnosis, management, and prevention of chronic obstuctive pulmonary disease. www.​goldcopd.​org. Accessed Feb 2013
4.
Zurück zum Zitat Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I et al (2009) Pneumonia guidelines committee of the BTS standards of care committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 64(Suppl 3):1–55CrossRef Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I et al (2009) Pneumonia guidelines committee of the BTS standards of care committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 64(Suppl 3):1–55CrossRef
5.
Zurück zum Zitat National Institute for Health and Care Excellence, National Clinical Guideline Centre, Chronic Obstructive Pulmonary Disease (2010) Management of chronic obstructive pulmonary disease in adults in primary and secondary care (CG101). http://guidance.nice.org.uk/CG101 National Institute for Health and Care Excellence, National Clinical Guideline Centre, Chronic Obstructive Pulmonary Disease (2010) Management of chronic obstructive pulmonary disease in adults in primary and secondary care (CG101). http://​guidance.​nice.​org.​uk/​CG101
6.
Zurück zum Zitat Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al (2007) Infectious diseases society of America; American thoracic society (2007) Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72PubMedCrossRef Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al (2007) Infectious diseases society of America; American thoracic society (2007) Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72PubMedCrossRef
7.
Zurück zum Zitat Celli BR, MacNee W, ATS/ERS Task Force (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 23:932–946 Celli BR, MacNee W, ATS/ERS Task Force (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 23:932–946
8.
Zurück zum Zitat Reissig A, Copetti R, Mathis G, Mempel C, Schuler A, Zechner P et al (2012) Lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia. A prospective multicentre diagnostic accuracy study. Chest 142:965–972PubMedCrossRef Reissig A, Copetti R, Mathis G, Mempel C, Schuler A, Zechner P et al (2012) Lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia. A prospective multicentre diagnostic accuracy study. Chest 142:965–972PubMedCrossRef
9.
Zurück zum Zitat National Committee for Clinical Laboratory Standards (2004) Performance standards for antimicrobial susceptibility testing, 14th informational supplement. Approved standard M100-S14. Wayne, PA: National Committee for Clinical Laboratory Standards National Committee for Clinical Laboratory Standards (2004) Performance standards for antimicrobial susceptibility testing, 14th informational supplement. Approved standard M100-S14. Wayne, PA: National Committee for Clinical Laboratory Standards
10.
Zurück zum Zitat Herrero FS, Olivas JB (2012) Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit Care Med 33:220–231CrossRef Herrero FS, Olivas JB (2012) Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit Care Med 33:220–231CrossRef
11.
Zurück zum Zitat Welte T, Köhnlein T (2009) Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ network. Semin Respir Crit Care Med 30:127–135PubMedCrossRef Welte T, Köhnlein T (2009) Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ network. Semin Respir Crit Care Med 30:127–135PubMedCrossRef
12.
Zurück zum Zitat Pletz MW, Rohde G, Schütte H, Bals R, von Baum H, Welte T (2011) Epidemiology and aetiology of community-acquired Pneumonia (CAP). Dtsch Med Wochenschr 136:775–780PubMedCrossRef Pletz MW, Rohde G, Schütte H, Bals R, von Baum H, Welte T (2011) Epidemiology and aetiology of community-acquired Pneumonia (CAP). Dtsch Med Wochenschr 136:775–780PubMedCrossRef
13.
Zurück zum Zitat Echols RM, Tillotson GS, Song JX, Tosiello RL (2008) Clinical trial design for mild-to-moderate community-acquired pneumonia—an industry perspective. Clin Infect Dis 47(Suppl 3):S166–S175PubMedCrossRef Echols RM, Tillotson GS, Song JX, Tosiello RL (2008) Clinical trial design for mild-to-moderate community-acquired pneumonia—an industry perspective. Clin Infect Dis 47(Suppl 3):S166–S175PubMedCrossRef
14.
Zurück zum Zitat Aliberti S, Blasi F, Zanaboni AM, Peyrani P, Tarsia P, Gaito S (2010) Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. Eur Respir J 36:128–134PubMedCrossRef Aliberti S, Blasi F, Zanaboni AM, Peyrani P, Tarsia P, Gaito S (2010) Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia. Eur Respir J 36:128–134PubMedCrossRef
15.
Zurück zum Zitat Li JZ, Winston LG, Moore DH et al (2007) Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a metaanalysis. Am J Med 120:783–790PubMedCrossRef Li JZ, Winston LG, Moore DH et al (2007) Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a metaanalysis. Am J Med 120:783–790PubMedCrossRef
Metadaten
Titel
Microbiological Diagnosis and Antibiotic Therapy in Patients with Community-Acquired Pneumonia and Acute COPD Exacerbation in Daily Clinical Practice: Comparison to Current Guidelines
verfasst von
Angelika Reissig
Christine Mempel
Ulrike Schumacher
Roberto Copetti
Florian Gross
Stefano Aliberti
Publikationsdatum
01.06.2013
Verlag
Springer-Verlag
Erschienen in
Lung / Ausgabe 3/2013
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-013-9460-x

Weitere Artikel der Ausgabe 3/2013

Lung 3/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.